They did a reverse merger with SNUS instead. $34 Mil in cash ($.50 per share) and four products (pre-clinical, stage 1 and 2). Currently trading at all time low of $.28 GLTY of $.28 GLTY
chapter 11- I just got off the phonw with the TA for SNRS. Authorized is 10 billion. Their computers were down but he told me he knew the outstanding was less than 1 billion, so I guess the best way to figure it is close to that number.